BeyondSpring, a biopharmaceutical company focused on cancer therapy, filed Tuesday to go public in an offering of up to $100 million. The company has operations in the United States and in China. The number of shares and price range have not yet been determined. The company has applied to list its stock on the Nasdaq Global Market under the symbol "BYSI." The offering is being underwritten by Citigroup, Guggenheim Securities and FBR.
Continue Reading Below
Copyright © 2016 MarketWatch, Inc.